Victory Capital Management
MBX

Victory Capital Management’s MBX Biosciences MBX Stock Holding History

Victory Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-71,028
Closed -$2.12M – 2576
2026
Q1 		$2.12M Buy
+71,028
New +$2.42M ﹤0.01% 1585

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Victory Capital Management's MBX Position: Q2 2026 in Review

Victory Capital Management sold out of MBX Biosciences (MBX) in Q2 2026, closing a stake of 71,028 shares — an estimated $2.12M sold.

Victory Capital Management first reported a position in MBX in Q1 2026 and held it in 1 quarter. The position peaked at $2.12M in Q1 2026. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Victory Capital Management reported no remaining MBX Biosciences position as of Q2 2026 after selling out during the quarter.
  • Victory Capital Management sold 71,028 MBX Biosciences shares in Q2 2026, an estimated $2.12M.
  • Victory Capital Management first reported a position in MBX Biosciences in Q1 2026 and held it in 1 quarter.
  • Victory Capital Management's MBX Biosciences position peaked at $2.12M in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.